Thursday, August 27, 2026

Fiscal Policy & Government Finance

2 articles

Social Security Insolvency Accelerates to 2032 as Tax Cuts Slash $1.1 Trillion in Revenue

Social Security Insolvency Accelerates to 2032 as Tax Cuts Slash $1.1 Trillion in Revenue

The One Big Beautiful Bill Act pushes Social Security fund depletion to 2032-2035 through tax cuts that reduce federal revenue by $1.1 trillion. Congressional Budget Office projections show automatic benefit cuts will hit when funds deplete, while only 24% of current beneficiaries gain tax relief. The collision arrives as Fed Chair Jerome Powell's term expires May 2026, creating monetary-fiscal policy uncertainty for investors.

ViaNews Editorial Team (Finance)
OBBBA Tax Cuts Could Push Social Security Insolvency to 2032, Threaten Bank Depositor Base

OBBBA Tax Cuts Could Push Social Security Insolvency to 2032, Threaten Bank Depositor Base

The One Big Beautiful Bill Act combines $1.1 trillion in federal spending cuts with tax relief that independent analysts warn could accelerate Social Security insolvency from 2035 to 2032. The Congressional Budget Office projects 11.8 million Americans will lose health insurance by 2034 due to Medicaid cuts, while 33% benefit reductions loom for Social Security recipients. Banks and insurers face a shrinking middle-class customer base as fiscal pressures mount.

ViaNews Editorial Team (Finance)
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com